High Point, NC, United States of America

Danilo Almariego

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Vtv Therapeutics LLC. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Danilo Almariego: Innovator in Pharmaceutical Compositions

Introduction

Danilo Almariego is a notable inventor based in High Point, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions for treating metabolic disorders.

Latest Patents

Danilo holds a patent for "Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof." This invention provides tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The patent further details solid compositions comprising these salts and their uses, particularly for treating type 1 diabetes, type 2 diabetes, or obesity. He has 1 patent to his name.

Career Highlights

Danilo is currently associated with Vtv Therapeutics LLC, where he continues to work on innovative solutions in the pharmaceutical industry. His expertise in the field has positioned him as a valuable asset to his company and the broader scientific community.

Collaborations

Danilo collaborates with esteemed colleagues, including Dharma Rao Polisetti and Eric Joel Benjamin. Their combined efforts contribute to advancing research and development in pharmaceutical innovations.

Conclusion

Danilo Almariego's work exemplifies the impact of innovation in healthcare, particularly through his patented compositions aimed at addressing critical health issues. His contributions are paving the way for new treatments in diabetes and obesity.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…